Featuring fresh research and in-depth case studies enabling you to:

- Go beyond QSAR prediction: utilise an innovative, translational, FDA-developed tool to save time, money and support safety assessments in multipurpose ways
- Harness novel computational and high-content tools to reduce idiosyncratic DILI failures: new findings from Merck Serono, Lundbeck and University College Dublin
- Identify and deselect cardiotoxic and proarrhythmic NMEs in silico: illustrated by Bayer and Oxford University
- Incorporate human and hiPSC-derived cells during R&D to effectively model torsade de pointes and QT prolongation: case studies from GSK and Janssen
- Integrate clinical findings into human mechanism-guided, new product development: apply lessons learned from Roche, Novartis and Gilead

Integrate mechanistic, translational tools using in silico, in vitro, in vivo and clinical strategies

Hear the latest case studies and expertise across therapeutic areas from over 16 speakers including:

- Luis Valerio Jr, Senior Toxicologist, FDA/CDER
- Peter Clements, Director of Pathology, GlaxoSmithKline
- Michael Merz, Director Preclinical Safety, Novartis
- David Gallacher, Senior Director, Janssen Pharmaceuticals
- Lucette Doessegger, Global Head of Licensing and Early Development, Roche
- Thomas Steger-Hartmann, Head of Investigational Toxicology, Bayer
- Philip Hewitt, Head of Early Non-Clinical Safety (Liver and Kidney), Merck Serono
- Franck Atienza, Head, In vitro Toxicology Unit, UCB
- Thomas Mow, Head of Safety Pharmacology, Lundbeck
- Gareth Waldron, Non-Clinical Safety Lead, Pfizer
- Sridharan Rajamani, Senior Personalized Healthcare Leader, Roche
- Harald Kropshofer, Senior Research Scientist, Gilead

www.predictivetoxicology.com